Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Jaafar Bennouna, Sandrine Hiret, Christophe Borg, Aurélie Bertaut, O. Bouche, G. Deplanque, Éric François, Thierry Conroy, François Ghiringhelli, G. Des Guetz,

Annals of Oncology · 2017 · 12 citations · 0 references

Concepts